Mentions
Extended reach
Total likes
Video views
AI synopsis
The group consistently highlights the remarkable weight loss results from tirzepatide, such as up to 21% loss over 72 weeks, and discusses its potential to revolutionize obesity management with enthusiastic language like 'game changer' and 'beginning of the end for diet gurus.' The tone is highly positive and analytical, supported by references to specific studies and clinical trial data, which demonstrates both high interest and engagement, and underscores the significant perceived impact of this research.
Most discussions highly support the research findings, emphasizing the drug's effectiveness.
Participants show strong interest, with many referencing specific studies and results.
Several discussions include detailed study data, references, and personal plans to share information, indicating deep engagement.
The posts suggest the research could drastically influence obesity treatment, with expectations of future use and policy changes.
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLancet https://t.co/PiZuBo4Or0 https://t.co/Jy3MK8t61E
Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/zp8DyOAiXB https://t.co/7PPkFcDp5M
About to do a video on the new weight loss study. I'm beyond excited about the implications this has to turn the tide on the obesity epidemic. Plus I think this signals the beginning of the end for weight loss and diet gurus (finally!) https://t.co/Yxk8R50RyH
A healthier future through pharmacotherapy awaits. Sources: https://t.co/x9J75jdSsP (P.S., SURPASS-5 was even more optimistic: https://t.co/N6dvG6Acjm) https://t.co/z0m0Bagx2y https://t.co/0qcNnNDMNA https://t.co/fp0CvBOeso https://t.co/daJovuxe8D More:
⚠️ Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial‼️ @TheLancet @secardiologia @almucastro01 @domingomarzal @MAROSFO https://t.co/u7iA6GuBV3 https://t.co/bRxR5ueh93
Tirzepatide, used for weight loss among non-diabetic individuals, is now available! DM us if interested! Read more about it here: (Philippine College of Endocrinology) https://t.co/JrMOhpdzSd (New England Journal of Medicine) https://t.co/OCeuCJTDo1 https://t.co/T8zrKKpDLk
Weight loss drugs Ozempic, Wegovy, and Mounjaro are discussed, covering how they work and their safety. This video explains their roles as GLP1 mimetics for obesity and weight management.
This video analyzes the effectiveness and cost of popular appetite suppressants, including Tesofensine and Tirzepatide, based on recent clinical data to inform better weight management choices.
This video explains how tirzepatide (Mounjaro) interacts with hormones GIP and GLP1 to regulate appetite, enhance insulin secretion, and promote weight loss, highlighting clinical study results, benefits, risks, and…
Obesity is a significant health issue globally. A Phase 3 trial shows tirzepatide, a new medication, leads to substantial weight loss—up to 20.9%—over 72 weeks in adults with BMI 30 or higher.
Explore the role of GLP-1 as a crucial hormone for regulating blood sugar and weight. This video examines GLP-1 receptor agonists like liraglutide and semaglutide, their benefits for glycemic control, weight loss, and…
Weight loss drug doesn't work in the first 12 weeks—keep using it until it works. This video summarizes the scientific evidence on tirzepatide's effectiveness for obesity treatment from a phase 3 clinical trial, showing…
This video explores the role of GLP-1 receptor agonists in addressing obesity and other health issues. It reviews recent innovations, their effectiveness in treating obesity, heart disease, and neurodegenerative…
Ozempic's days are numbered. A new diabetes medication approved in Brazil, Mounjaro, surpasses Ozempic in weight loss, but what are its side effects and precautions? Learn essential information about this innovative…
This video discusses Mounjaro, the new medication gaining attention for its impressive results in weight loss and type 2 diabetes treatment. We explore how tirzepatide, a long-acting GIP receptor agonist, enhances…
Explore the effectiveness of GLP-1 drugs like Ozempic, Wegovy, and Mounjaro for weight loss, with up to 20% reduction. Learn how they work, potential side effects, and long-term impact. Discover who benefits most and…
Beyond the Scales discusses the impact of ultraprocessed foods on weight control, featuring insights from medical students and a bariatric surgeon. The episode covers medications like semaglutide, orlistat, and GLP1…
This week, John Mandrola MD discusses the effectiveness of subcutaneous and transvenous implantable cardioverter-defibrillators (ICDs). The study shows similar rates of end-point events but highlights fewer…
This week's podcast discusses renal denervation, FDA approvals, and recent findings on ED risks and tirzepatide for obesity treatment, providing key updates for healthcare professionals.
While Ozempic may lead to muscle loss, proper nutritional and physical support can minimize or reverse it. Focus on supporting muscle health during weight loss for a healthier body composition.
@BenBear73068268 @AlexJLeaf Google this title, links disappear "Tirzepatide Once Weekly for the Treatment of Obesity"
こちらは、ベンチマークとなるチルゼパチド https://t.co/0xpwc2zmjK
減量すれば筋肉もある程度落ちるのは生理学的に当然。筋肉を全く落とさず痩せるのはボディビルの世界。大事なのは“比率”で、マンジャロはむしろ脂肪優位に減らすデータが出てます。 NEJM 2022: https://t.co/RYKraDTj86 Cureus 2025: https://t.co/g5rIMd1ooJ https://t.co/9DZ1CkgU5C
Tirzepatide Once Weekly for the Treatment of Obesity | New England Journal of Medicine #MounjaroMusings @NEJM https://t.co/QjkmpKzEYK
Compounded Tirzepatide Scientific Journal proving that its effective in adult age males & females by the New England Journal of Medicine: https://t.co/mxGOnifqPK
Compounded Tirzepatide Scientific Journal proving that its effective in adult age males & females by the New England Journal of Medicine: https://t.co/PurW90HQYM
Compounded Tirzepatide Scientific Journal proving that its effective in adult age males & females by the New England Journal of Medicine: https://t.co/SqkAqWCzs7
Tirzepatide Scientific Journal proving that its effective in adult age males & females by the New England Journal of Medicine: https://t.co/JBkgh40GJv
@NftFlood @williedunnam @Paddy_Barrett @grok https://t.co/LZLHjTCiRW
RT @cremieuxrecueil: A healthier future through pharmacotherapy awaits. Sources: https://t.co/x9J75jdSsP (P.S., SURPASS-5 was even more o…
RT @cremieuxrecueil: A healthier future through pharmacotherapy awaits. Sources: https://t.co/x9J75jdSsP (P.S., SURPASS-5 was even more o…
A healthier future through pharmacotherapy awaits. Sources: https://t.co/x9J75jdSsP (P.S., SURPASS-5 was even more optimistic: https://t.co/N6dvG6Acjm) https://t.co/z0m0Bagx2y https://t.co/0qcNnNDMNA https://t.co/fp0CvBOeso https://t.co/daJovuxe8D More:
✅ https://t.co/9xbiBzuptA ✅ https://t.co/VZkUA2HgN5 ✅ https://t.co/pbaAzWfBWA ✅ https://t.co/EgJ07jp9XD Turns out Tirzepatide can fix a lot of problems! Yay science! https://t.co/JlYxXoWA2t
@TheEcho13 The current studies in GLP-1s for weight loss are all running approximately 70% female. SURMOUNT-1 supplementary appendix. They’re all like this. https://t.co/lNI0GJmUl9
1/ Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates profound cardiometabolic benefits beyond weight loss, as revealed in a new analysis from the SURMOUNT-1 trial. This thread explores its transformative potential in obesity management. https://t.co/pK3XXvMrXo
@tehseenp Yes there are side effects and needs to be monitored closely. https://t.co/n1I3JXUtWs https://t.co/r508EbK1xT https://t.co/ickuubZa43
SURMOUNT-1 studija je testirala novi lek tirzepatid (Mounjaro), koji je pomogao osobama sa gojaznošću da izgube više od 20% svoje telesne mase. Lek je uglavnom bio bezbedan, iako su neki imali blage do umerene, dominantno stomačne tegobe. https://t.co/50iiyWOT0R https://t.co/KcdOQyp8dP
@cremieuxrecueil Graph from the 2022 NEJM paper on tirzepatide (Mounjaro) for weight loss https://t.co/BVC1okGLNX
@osint_leon @StefanoBerto83 Visto che usi la tirzepatite (che è sempre un antagonista del recettori degli ormoni incretine GLP-1 e GIP) conoscerai questo studio di fase 3 randomizato su 2539 Adulti durato 5 mesi di aumento della dose + 1 anno a dose piena https://t.co/fNBlvouElY 1/
Tirzepatida
Is dropping back down in dose "micro-dosing" - or is it doing exactly what the clinical trials did... Patients could drop back 1 dose level.
RT @AdrianMDPhD: Tirzepatide, used for weight loss among non-diabetic individuals, is now available! DM us if interested! Read more about…
RT @AdrianMDPhD: Tirzepatide, used for weight loss among non-diabetic individuals, is now available! DM us if interested! Read more about…
@moonrunsunbike1 Agreed, I use tirzepatide if needed. However, we still were better than tirzepatide at the >5% weight loss threshold in SURMOUNT 1 (Us: 95%, them: 91%) https://t.co/Bp6z8K4eRy https://t.co/NoHG9zsfNk
RT @AdrianMDPhD: Tirzepatide, used for weight loss among non-diabetic individuals, is now available! DM us if interested! Read more about…
RT @AdrianMDPhD: Tirzepatide, used for weight loss among non-diabetic individuals, is now available! DM us if interested! Read more about…
RT @AdrianMDPhD: Tirzepatide, used for weight loss among non-diabetic individuals, is now available! DM us if interested! Read more about…
RT @AdrianMDPhD: Tirzepatide, used for weight loss among non-diabetic individuals, is now available! DM us if interested! Read more about…
Tirzepatide, used for weight loss among non-diabetic individuals, is now available! DM us if interested! Read more about it here: (Philippine College of Endocrinology) https://t.co/JrMOhpdzSd (New England Journal of Medicine) https://t.co/OCeuCJTDo1 https://t.co/T8zrKKpDLk
@debianloco https://t.co/eUmDHENcjw https://t.co/jWji5FXbdY
@MorseBart @DrNadolsky https://t.co/aIsqZyyouI
RT @DanielJDrucker: In SURMOUNT-1 studying tirzepatide the weight loss from a baseline of ~104.8kg was 20.9% at 72 wks. In the Amycretin P2…
RT @DanielJDrucker: In SURMOUNT-1 studying tirzepatide the weight loss from a baseline of ~104.8kg was 20.9% at 72 wks. In the Amycretin P2…
In SURMOUNT-1 studying tirzepatide the weight loss from a baseline of ~104.8kg was 20.9% at 72 wks. In the Amycretin P2A trial, the baseline weight was 92.7kg https://t.co/8laLhOB1UE
@BioboostDaily @RedPillMD @DrPlantel https://t.co/wfzA7GCmFR
RT @robertlufkinmd: Tirzepatide: In the SURMOUNT-1 trial, weight reduction percentages were dose-dependent: 5 mg: ~15.0% weight reduction.…
RT @robertlufkinmd: Tirzepatide: In the SURMOUNT-1 trial, weight reduction percentages were dose-dependent: 5 mg: ~15.0% weight reduction.…
Tirzepatide: In the SURMOUNT-1 trial, weight reduction percentages were dose-dependent: 5 mg: ~15.0% weight reduction. 10 mg: ~19.5% weight reduction. 15 mg: ~20.9% weight reduction (Jastreboff et al., 2022). https://t.co/Gi3i8zQscV https://t.co/TCULKwVKgP @GatlanHealth  https://t.co/FvoEfRb2t1
@JayZaleski864 @cigs1234 https://t.co/B9KhPTUW19 https://t.co/Nh78ExC5bw
@cgengomics @KNielsen2000 @GilaMonstrum https://t.co/ylUioSYNGm Have to look at 12 week efficacy in the graphs. There is no 12 week adverse event data. We are comparing over a year of Lilly tolerability data to only 13 weeks of $VKTX tolerability data (another reason it is an unfair comparison for $LLY).
@molliekatie @ddiamond Perhaps you should just like read a study about these drugs because this was well publicized. Over the 9mos where everyone got tirzepatide they lost avg 21% body weight, after ~1yr off it (on placebo) avg net 10% loss. From https://t.co/x0THd7V1xq and https://t.co/ZJE8Tt5hj2 https://t.co/Hf8PVPpgr7
Tirzepatide Once Weekly for the Treatment of Obesity #weightloss https://t.co/7fMXj1ZU0C
Parece que la tirzepatida va a ser un ozempic 2.0, promete revertir la diabetes en el 99% de los enfermos y bajar de peso como ya se sabía con otros agonistas de glp1. https://t.co/GzbJDJoarO https://t.co/EGhscSjmK6
(Mounjaro) The safety profile of tirzepatide was consistent with previous findings in the … trials in patients with type 2 diabetes… mostly mild-to-moderate GI events were the most reported adverse events, occurring primarily during dose-escalation. https://t.co/7r0O19VZL1 https://t.co/Nc7YHmYB8p
@thestoptv (Mounjaro) The safety profile of tirzepatide was consistent with previous findings in the … trials in patients with type 2 diabetes… mostly mild-to-moderate GI events were the most reported adverse events, occurring primarily during dose-escalation. https://t.co/7r0O19VZL1
Normally, the %FFM lost is presented relative to total BW. The original paper showed that the decrement in %FFM was 10.9 % (normalized by total BW) and not 40% (data obtained after normalizing by the weight lost) over 36-72 weeks. https://t.co/iSswziwUu4. https://t.co/u49upqO5e6
@bickley200 “Supported by Eli Lilly. Disclosure forms provided by the authors are available with the full text of this article at https://t.co/1nKal1q246.” https://t.co/iU4GdtR4IJ
@bickley200 “There were 160 participants with serious adverse events in this trial.“ https://t.co/T16VuB5F53
@bickley200 “Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively.” https://t.co/T16VuB5F53
Tirzepatide, a dual GLP1/GIP agonist, is said to cause less lean mass loss issues than semaglutide 2.4 mg In the SURMOUNT-1 trial the total lean mass lost is ~24.3% (i.e. 33.9 + 10.9 / 10.9 = 0.2433) https://t.co/NaHRavhbpb https://t.co/E4hRKPWneH
Les agonistes des récepteurs GLP-1 peuvent aussi entraîner une perte importante de muscle, représentant entre 25% et 39% du poids perdu. Cela peut poser problème pour la santé musculaire à long terme https://t.co/YXNI5spDx0 https://t.co/9lDeaVsI3m
每周使用 Tirzepatide 治疗肥胖症 | 新英格兰医学杂志 https://t.co/rw7zvhnDmQ
@jesse_brodkin And the monluna exclusion criteria you posted above are essentially the exact same as what Lilly used for tirzepatide development, all the way down to which medications are permitted/rejected (SSRIs are ok *except* for paroxetine). https://t.co/hSZVojSoKh
Are #Ozempic and #Mounjaro foolproof for weightloss? Follow the protocol from the huge SURMOUNT-1 study to really lose the weight: ≥150 minutes exercise/week 500 calorie deficit/day 30% fat/20% protein/50% carbs Regular diet and lifestyle counseling https://t.co/bon1qOxiEn
RT @neurohuerta: Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3)…
@vicentmarti_ @IbaiLlanos Este estudio con Zepbound (siguiente generación) también muestra lo mismo. Pérdida de grasa pero también pérdida de músculo. https://t.co/ySluzFB6Te
@mackinprof GLP1a versus VLCD? Context: Very true for obesity. But type 2 diabetes? OBESITY -Low Carb: https://t.co/O89rFEmWfr (~10%) -TRZ: https://t.co/wvEdk27w1l (~21%) T2D -Low Carb: https://t.co/kQ9ZHaVjoo (12%) -TRZ: https://t.co/Bmm3UCYlCM (12%) I am sure as GLP1a https://t.co/D48bDGQBfR
@Christo94622078 @EricTopol The tirzepatide figure is from a cherry-picked 255 patient subgroup. It's not comparable to a full population analysis (see original NEJM study). Retatrutide is a triple agonist so it's not purely a glucagon agonist like pemvidutide or survodutide. https://t.co/zKzIqFx4cR
@RonnyWW @lelysses @GemDrgn @janejupiterxx @BMcblueface @upzone_CA The groups were treated identically; the trial was fully blinded so nobody knew who was on placebo vs meds. They weren’t confined to a metabolic ward so compliance was self-reported for both groups. The trial is here: https://t.co/aIsqZyyouI
https://t.co/7Xbb4hICym
https://t.co/7Xbb4hICym
#يحدث_الآن Tirzepatide A Promising Treatment for Obesity
Calling all docs and nurses. What’s your opinion of https://t.co/sDcGAtBiGE @DoctorZywiec @MdBreathe @InformedNJNurse @CardioFixer
RT @toddscarbrough: NB: Many cancer risks are associated with obesity https://t.co/ZDMQNNv15Q In the NEJM: phIII trial in obese pts with…
The weight is over
@fabyfalcao Tirzepatida (Mounjaro) foi estudado para obesidade. https://t.co/T9Sq6wJ1Lf
Ref: NEJM: Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/A8eTlBQRtB? https://t.co/TVd6z5jeVh
2/ Tirzepatide Once Weekly for the Treatment of Obesity | NEJM https://t.co/GmW68XbPP2
RT @gF1EmnrVteANzE6: @v_fachiri @MR_DIECOCK 何で、脳血液関門が5G で開くとか言ってるバカのコメント 訳す必要があるんだ？☺️ それより、これ読もうぜ。 GLP1作動薬。 劇的に効く抗肥満薬。 まあ、膵炎とかのリスクは あるが、C…
@v_fachiri @MR_DIECOCK 何で、脳血液関門が5G で開くとか言ってるバカのコメント 訳す必要があるんだ？☺️ それより、これ読もうぜ。 GLP1作動薬。 劇的に効く抗肥満薬。 まあ、膵炎とかのリスクは あるが、CVDリスクも減るし 良いようだよ https://t.co/mbBamw7uSP
@pharmdaz Glad to cite my factually, objectively, inarguably correct statements: First paragraph under "Participants": https://t.co/QQzLWO08Cx Slide 23: https://t.co/KioMoYBX2D
https://t.co/BFFT5tu5IO
RT @alberthenriquez: @RompeCadenaz @immuno458 Uno nuevo... Tirzepatide https://t.co/Tgtgyh7Fqo
@RompeCadenaz @immuno458 Uno nuevo... Tirzepatide https://t.co/Tgtgyh7Fqo
Tirzepatide Once Weekly for the Treatment of Obesity #weightlosss https://t.co/7fMXj1ZU0C
‘It’s a new era’: Weight-loss treatments significantly lower blood pressure | NEJM https://t.co/tlfABq4rSl
RT @DanielJDrucker: The challenge of #obesity therapeutics will be extensively discussed #KSobesity24 with the giant shadow of amazing Tirz…
RT @DanielJDrucker: The challenge of #obesity therapeutics will be extensively discussed #KSobesity24 with the giant shadow of amazing Tirz…
RT @DanielJDrucker: The challenge of #obesity therapeutics will be extensively discussed #KSobesity24 with the giant shadow of amazing Tirz…
The challenge of #obesity therapeutics will be extensively discussed #KSobesity24 with the giant shadow of amazing Tirzepatide ever present. Is adding GIP agonism to the mix the secret for future success? How to mechanistically reconcile data for AMG-133? https://t.co/8laLhOAu56?
Eli Lilly has developed Mounjaro® (tirzepatide) - a new class of treatment for obesity and type 2 Diabetes. This innovative therapy, backed by preclinical data from the #PhenoMaster marks a significant step towards a healthier future. Learn more: https://t.co/Q6RHEOtpTb #Obesity https://t.co/ve1ixcomDg
@HumanOnlyBeing @SBakerMD https://t.co/aIsqZyxQFa
@SGodfreyHendrix @AliceFromQueens Page 24 for tirzepatide body comp: https://t.co/mqhbzYyV9R
@SGodfreyHendrix @ChMark161 @AliceFromQueens @Ecclesiasticu12 @DanielHadas2 @yianni_s00 @ClickingSeason Graphic is from here: https://t.co/aIsqZyyouI
@CNFT_GC @GoldshteynYulia @DrNadolsky Full study is here. https://t.co/aIsqZyxQFa
from an earlier study, it's striking how effective even 5mg/week Tirzepatide is: 15% weight loss for 5mg 19.5% for 10mg 20.9% for 15mg https://t.co/vGlocbY7zy https://t.co/8dUFU2kwHT
@MichaelAlbertMD @CardioNerdsJC Another example, SURMOUNT-1 - 67% women https://t.co/ZMpOrqAoNR
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038 Leslie M. Hot weight loss drugs tested against addiction. Science. 2023;381(6661):930-931. doi:10.1126/science.adk5720
RT @HanchateShivani: 8/
RT @HanchateShivani: 8/
RT @HanchateShivani: 8/
8/
@giglionejunio Podemos discutir o estudo em questão juntos e avaliar seu desenho, poder e limitações. Tirzepatide Once Weekly for the Treatment of Obesity DOI: 10.1056/NEJMoa2206038 O que você me diria sobre o desenho, tamanho da amostra e conclusões? Se desejar conversar sobre, adoraria um
@DG79427252 Vou deixar aqui o título acompanhado do DOI, para que todos possam ter acesso: Tirzepatide Once Weekly for the Treatment of Obesity DOI: 10.1056/NEJMoa2206038
RT @EricTopol: Not every day there's an anti-obesity drug that leads to 15-20% body weight loss https://t.co/5jiUjsV5nB recently @US_FDA a…
Fuente: https://t.co/0lNSOUQdD3 #AMG2023 #academiayciencia #yosoyAMG https://t.co/t698Oi4xn0
Tirzepatide Once Weekly for the Treatment of Obesity | NEJM https://t.co/VjfrU7R4i9 https://t.co/JcG1Co62Iq
RT @EricTopol: Not every day there's an anti-obesity drug that leads to 15-20% body weight loss https://t.co/5jiUjsV5nB recently @US_FDA a…
Haven’t read SURMOUNT 1 yet? 5/10/15mg Tirzepatide lead to -15%, -19.5% and -20.9% weight loss respectively at 72 weeks
Grappig, wel, dat de groep die de placebo kreeg in gemiddeld 3% gewicht verloor. Ik vermoed daar het effect van de 'lifestyle intervention' en het effect van extra motivatie er nu écht eens iets aan te doen, met het idee dat de spuiten erbij helpen. https://t.co/AKQYhQlkaI https://t.co/wpJuGQSmIa
Tirzepatide Once Weekly for the Treatment of Obesity. GLP-1/GIP双通道受体激动剂Tirzepatide治疗未患糖尿病的肥胖或超重成年人疗效和安全性研究“SURMOUNT-1”研究结果:不同剂量(5mg,10mg,15mg)Tirzepatide均可显著,持续地减轻肥胖患者体重,最高剂量组,72周平均减重48斤. https://t.co/bOTQ6euS7d
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial - The Lancet https://t.co/mTG5KTrlNM
Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/7fMXj1ZU0C
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial - The Lancet https://t.co/jRAt0SP7hY
RT @JTLLERGO: ⚠️ Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomis…
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial - The Lancet https://t.co/mTG5KTrlNM
RT @JTLLERGO: ⚠️ Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomis…
RT @NeilFlochMD: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomis…
RT @JTLLERGO: ⚠️ Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomis…
RT @JTLLERGO: ⚠️ Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomis…
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
RT @JTLLERGO: ⚠️ Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomis…
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
RT @JTLLERGO: ⚠️ Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomis…
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
RT @FormigaFrancesc: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, rand…
Tirzepatide once weekly for the treatment of obesity in people with ty... https://t.co/WNKMmm9nMR
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial - ScienceDirect https://t.co/YnTfnFxmuQ
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
RT @JTLLERGO: ⚠️ Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomis…
RT @JTLLERGO: ⚠️ Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomis…
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
RT @JTLLERGO: ⚠️ Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomis…
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
RT @JTLLERGO: ⚠️ Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomis…
RT @JTLLERGO: ⚠️ Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomis…
RT @JTLLERGO: ⚠️ Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomis…
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
RT @JTLLERGO: ⚠️ Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomis…
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
RT @JTLLERGO: ⚠️ Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomis…
⚠️ Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial‼️ @TheLancet @secardiologia @almucastro01 @domingomarzal @MAROSFO https://t.co/u7iA6GuBV3 https://t.co/bRxR5ueh93
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
RT @kamleshkhunti: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLa…
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial - The Lancet https://t.co/uvc0F8le4Y
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) now published in @TheLancet https://t.co/PiZuBo4Or0 https://t.co/Jy3MK8t61E
Tirzepatide Once Weekly for the Treatment of Obesity in People With Type 2 Diabetes https://t.co/NSLW1Hg4Tl via @practiceupdate
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial https://t.co/ws50UUSwYC
@Thue_Schwartz Yes, but not in SURMOUNT-2: “Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial” https://t.co/vVnbzszcnL
RT @CristobMorales: https://t.co/yebusbtUgA Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2…
Tirzepatide Once Weekly for the Treatment of Obesity | NEJM https://t.co/LGl4umibEr
RT @BradStanfieldMD: References: https://t.co/ifEDAxTBYn https://t.co/cuht9mtbqp https://t.co/vpEzuNCUFf https://t.co/lpHy2pBHLH
References: https://t.co/ifEDAxTBYn https://t.co/cuht9mtbqp https://t.co/vpEzuNCUFf https://t.co/lpHy2pBHLH
Tirzepatide Once Weekly for the Treatment of Obesity | NEJM https://t.co/Xm66BQGVyL
[Articles] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial #science #publication #research #journal https://t.co/c0XDbQMYv2
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial https://t.co/T5xKA5jRC3 https://t.co/ZZkXoka6im
RT @CristobMorales: https://t.co/yebusbtUgA Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2…
RT @CristobMorales: https://t.co/yebusbtUgA Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2…
RT @CristobMorales: https://t.co/yebusbtUgA Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2…
[Articles] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial #science #publication #research #publications https://t.co/SF5SNcJ4uz
RT @CristobMorales: https://t.co/yebusbtUgA Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2…
RT @cristinatejerap: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, ra…
RT @cristinatejerap: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, ra…
RT @TheLancet: Tirzepatide once weekly for the treatment of obesity in people with type 2 #diabetes (SURMOUNT-2): a double-blind, randomise…
RT @CristobMorales: https://t.co/yebusbtUgA Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2…
RT @CristobMorales: https://t.co/yebusbtUgA Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2…
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial https://t.co/u7rGoAgoQi
RT @CristobMorales: https://t.co/yebusbtUgA Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2…
RT @CristobMorales: https://t.co/yebusbtUgA Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2…
RT @CristobMorales: https://t.co/yebusbtUgA Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2…
RT @TheLancet: Tirzepatide once weekly for the treatment of obesity in people with type 2 #diabetes (SURMOUNT-2): a double-blind, randomise…
RT @TheLancet: Tirzepatide once weekly for the treatment of obesity in people with type 2 #diabetes (SURMOUNT-2): a double-blind, randomise…
RT @TheLancet: Tirzepatide once weekly for the treatment of obesity in people with type 2 #diabetes (SURMOUNT-2): a double-blind, randomise…
Tirzepatide once weekly for the treatment of obesity in people with type 2 #diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
RT @CristobMorales: https://t.co/yebusbtUgA Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2…
RT @redGDPS: Mas bibliografia https://t.co/sloGkBm8kr
RT @redGDPS: Mas bibliografia https://t.co/sloGkBm8kr
RT @CristobMorales: https://t.co/yebusbtUgA Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2…
RT @cristinatejerap: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, ra…
RT @CristobMorales: https://t.co/yebusbtUgA Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2…
RT @CristobMorales: https://t.co/yebusbtUgA Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2…
Mas bibliografia https://t.co/sloGkBm8kr
RT @CristobMorales: https://t.co/yebusbtUgA Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2…
RT @CristobMorales: https://t.co/yebusbtUgA Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2…
RT @CristobMorales: https://t.co/yebusbtUgA Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2…
RT @CristobMorales: https://t.co/yebusbtUgA Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2…
RT @CristobMorales: https://t.co/yebusbtUgA Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2…
RT @CristobMorales: https://t.co/yebusbtUgA Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2…
Pues aprovechando haciendo el curso de manejo de obesidad, recordar este articulo que comentan los Profes Tirzepatide Once Weekly for the Treatment of Obesity | NEJM https://t.co/z0dvB9hvZA
Battle Of The OVERPRICED Appetite Suppressants | Tesofensine Vs. Tirzepa... https://t.co/NhGc97NYW6 via @YouTube #helpYOUgetGAINS https://t.co/GWTnVtOqSq
New analysis shows improved #bodycomposition with tirzepatide is consistent across adult age groups @nejm https://t.co/y5Qf5GYgdu https://t.co/zfkZadjwTO
How effective is #tirzepatide for weight loss? The #SURMOUNT1 study of participants with overweight or obesity (but not T2D) showed participants who received the 15mg dose lost up to 22.5% of their body weight at 72 weeks. https://t.co/WZp6SWYAAh
マンジャロも、FDAがファストトラックで肥満症の適応とったら、英国、日本の追随も早いかもしれませんね。 https://t.co/W1ISo6T1uG
@Office_j まもなく販売のチルゼパチドは 体重減少20％・・ 血圧、A1cも下げるのでCVイベント大きく低下する結果がでれば良いのだが
RT @KyleKettlerMD: @AlecStapp @ArmandDoma This is the study you’re looking for: average roughly 20% weight loss in the tirzepatide group ht…
@AlecStapp @ArmandDoma This is the study you’re looking for: average roughly 20% weight loss in the tirzepatide group https://t.co/cDAVYNpdyb
Pero en los últimos años se han producido avances muy importantes en el tratamiento farmacológico y quirúrgico de la obesidad que deberían motivarnos a lograr esos objetivos. Especialmente brillantes son los resultados con agonistas del receptor GLP-1
@Quartzgirl06 @juliaoftoronto https://t.co/F1DtY4D33j
@martijnkatan Fascinerend, bedankt! Vanuit de farmaceuten bezien is dit natuurlijk een goudmijn, dus niet verwonderlijk dat het duur is (en misschien moeilijk om te maken). Voor wie mee leest: https://t.co/HDpVezMbnp
@TheSalonniere @mwr_dbm @ProNotCon @SpikeDna @GidMK Tirzepatide once weekly results in 17.8% body weight reduction over placebo at highest dose. For someone who weighs 250 lbs that’s 44.5 lbs of excess weight loss over placebo https://t.co/cDAVYNpdyb
@monicaammoura @Dvdfsousa @nunocalvin2 https://t.co/HR6WA3MeX0
RT @SaulNutri:
RT @SaulNutri:
RT @Drlipid: Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/zp8DyOAiXB https://t.co/7PPkFcDp5M
En personas con obesidad, tirzepatide una vez por semana proporciona una reducción sustancial y sostenida del peso en tratamiento durante 72 sem #bodyweight #tirzepatide https://t.co/OLuxdehQcG
RT @AmCollegeGastro: 1/⏰for another #EBGI
RT @AmCollegeGastro: 1/⏰for another #EBGI
RT @AmCollegeGastro: 1/⏰for another #EBGI
RT @AmCollegeGastro: 1/⏰for another #EBGI
RT @AmCollegeGastro: 1/⏰for another #EBGI
RT @AmCollegeGastro: 1/⏰for another #EBGI
RT @AmCollegeGastro: 1/⏰for another #EBGI
RT @AmCollegeGastro: 1/⏰for another #EBGI
RT @AmCollegeGastro: 1/⏰for another #EBGI
RT @AmCollegeGastro: 1/⏰for another #EBGI
RT @AmCollegeGastro: 1/⏰for another #EBGI
RT @AmCollegeGastro: 1/⏰for another #EBGI
RT @AmCollegeGastro: 1/⏰for another #EBGI
1/⏰for another #EBGI
RT @saud_alshehry_: @Nasser_bn_aboud هو في الأصل علاج سكر النوع الثاني ووجدت عليه دراسات اجريت هذا العام نشرتها مجلة نيو انجلاند الطبية تدع…
@Nasser_bn_aboud هو في الأصل علاج سكر النوع الثاني ووجدت عليه دراسات اجريت هذا العام نشرتها مجلة نيو انجلاند الطبية تدعم استخدامه لخفض الوزن https://t.co/dXh4hIYysm آثاره الجانبية المعروفة الغثيان والاحساس بالجوع أقل هل له آثار جانبية على البنكرياس؟ لا أعلم.
Diabetes drug helps patients lose never-before-seen amounts of weight, new study shows https://t.co/vUbkGtaXNL https://t.co/03U1UqYZU7 https://t.co/o3BVHRu6He
RT @iamritu: #ESCCongress New weight loss class of Rx: Tirzepatide
RT @iamritu: #ESCCongress New weight loss class of Rx: Tirzepatide
RT @iamritu: #ESCCongress New weight loss class of Rx: Tirzepatide
RT @iamritu: #ESCCongress New weight loss class of Rx: Tirzepatide
RT @iamritu: #ESCCongress New weight loss class of Rx: Tirzepatide
RT @iamritu: #ESCCongress New weight loss class of Rx: Tirzepatide
RT @iamritu: #ESCCongress New weight loss class of Rx: Tirzepatide
#ESCCongress New weight loss class of Rx: Tirzepatide
RT @Drlipid: Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/zp8DyOAiXB https://t.co/7PPkFcDp5M
RT @liubinyang: Impressive 20% weight reduction with Tirzepatide Once Weekly for the Treatment of Obesity! https://t.co/A1lA1H3Vua
Impressive 20% weight reduction with Tirzepatide Once Weekly for the Treatment of Obesity! https://t.co/A1lA1H3Vua
/3 studies https://t.co/R84LJ4Px0O https://t.co/tr8Mb9LvTR https://t.co/aHxDGdZ7Rc Short of eliminating mosquito-borne diseases hard to think of way to save more human life-years. Endocrinology indeed THE systems medicine @atulbutte end/
Tirzepatide Once Weekly for the Treatment of Obesity | NEJM https://t.co/D2a05j6kf9
Инъекции один раз в неделю нового комбинированного препарата Тирзепатида больным с ожирением, привели к такой же потере веса, как и бариатрическая хирургия. Смущает только цена.) https://t.co/dihKEo9R5K
https://t.co/f4BxoKimdI
Ca va mettre quelques chirurgiens bariatriques au chômage ce truc... https://t.co/tijylLRdFD
RT @SABOURETCardio: #Tirzepatide Once Weekly for #Obesity. Impressive #WeightLoss but #diet and #physicalactivities are still mandatory to…
RT @Drlipid: Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/zp8DyOAiXB https://t.co/7PPkFcDp5M
RT @Drlipid: Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/zp8DyOAiXB https://t.co/7PPkFcDp5M
RT @Drlipid: Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/zp8DyOAiXB https://t.co/7PPkFcDp5M
RT @Drlipid: Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/zp8DyOAiXB https://t.co/7PPkFcDp5M
RT @Drlipid: Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/zp8DyOAiXB https://t.co/7PPkFcDp5M
RT @Drlipid: Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/zp8DyOAiXB https://t.co/7PPkFcDp5M
RT @Drlipid: Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/zp8DyOAiXB https://t.co/7PPkFcDp5M
RT @SABOURETCardio: #Tirzepatide Once Weekly for #Obesity. Impressive #WeightLoss but #diet and #physicalactivities are still mandatory to…
RT @SABOURETCardio: #Tirzepatide Once Weekly for #Obesity. Impressive #WeightLoss but #diet and #physicalactivities are still mandatory to…
RT @SABOURETCardio: #Tirzepatide Once Weekly for #Obesity. Impressive #WeightLoss but #diet and #physicalactivities are still mandatory to…
RT @Drlipid: Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/zp8DyOAiXB https://t.co/7PPkFcDp5M
RT @Drlipid: Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/zp8DyOAiXB https://t.co/7PPkFcDp5M
RT @Drlipid: Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/zp8DyOAiXB https://t.co/7PPkFcDp5M
RT @Drlipid: Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/zp8DyOAiXB https://t.co/7PPkFcDp5M
RT @SABOURETCardio: #Tirzepatide Once Weekly for #Obesity. Impressive #WeightLoss but #diet and #physicalactivities are still mandatory to…
RT @SABOURETCardio: #Tirzepatide Once Weekly for #Obesity. Impressive #WeightLoss but #diet and #physicalactivities are still mandatory to…
RT @Drlipid: Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/zp8DyOAiXB https://t.co/7PPkFcDp5M
RT @Drlipid: Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/zp8DyOAiXB https://t.co/7PPkFcDp5M
#Tirzepatide Once Weekly for #Obesity. Impressive #WeightLoss but #diet and #physicalactivities are still mandatory to decrease #CVR https://t.co/a5Fgxjm9cF
RT @Drlipid: Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/zp8DyOAiXB https://t.co/7PPkFcDp5M
RT @Drlipid: Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/zp8DyOAiXB https://t.co/7PPkFcDp5M
RT @Drlipid: Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/zp8DyOAiXB https://t.co/7PPkFcDp5M
RT @Drlipid: Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/zp8DyOAiXB https://t.co/7PPkFcDp5M
RT @Drlipid: Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/zp8DyOAiXB https://t.co/7PPkFcDp5M
Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/zp8DyOAiXB https://t.co/7PPkFcDp5M
RT @rogersmcintyre: More research with incretins(e.g. liraglutide,semaglutide)and perhaps combined glp/gip agents (e.g.tirzepatide)in perso…
More research with incretins(e.g. liraglutide,semaglutide)and perhaps combined glp/gip agents (e.g.tirzepatide)in person with mental illness and obesity would be very interesting!more than 20% weight loss;benefit on brain function ?https://t.co/tIxzbSCbx6
Anti-obesity drugs are getting really good. 72 week study with ~2500 people showed an average weight loss of 15%-20% of body weight depending on dose https://t.co/MoroFRsxm5
Promising new therapy for weightloss! Heart health, blood sugar control, hormones, and sexual function all improve with weightloss! https://t.co/Goum0vkoMT
Tirzepatide Once Weekly for the Treatment of Obesity | NEJM https://t.co/c2XepcPcVI Can’t wait for this to reach Malaysian shores. 2025 perhaps?
Amazing weight loss results in the Tizepatide trial! Mean % change in weight with 15mg weekly dose at 72 weeks was -21% vs placebo -3%. Is this close to any bariatric surgical procedure? Obesity Medicine Association Obesity Action…https://t.co/8omJ0FvlIC https://t.co/coQHxT266L
非DM患者の肥満(平均108kg, BMI 38, 1つ以上の肥満関連合併症あり; HTN,DL,SASなど)に対してチルゼパチドは用量依存性に減量効果を示した。スポンサーはイーライリリー。 https://t.co/iqYENY8mbJ
Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/cpENNg0emb
Tirzepatide Once Weekly for the Treatment of Obesity - Remarkable and 1/3 cost of GLP1. Good news welcome these days https://t.co/HjHvXC84nz
RT @4nRR: Uso de Tirzepatide para el tratamiento de la obesidad ✌
Uso de Tirzepatide para el tratamiento de la obesidad ✌
5/6 In Brief article: "Tirzepatide to treat obesity: phase III results" read here: https://t.co/tcW7EhcKTT Original article: Jastreboff, A. M. et al., N. Engl. J. Med. (2022) https://t.co/xMW25UBZjG
RT @Bioredom1: Phase III results of Tirzepatide (GLP1 agonist) results in mean weight changes up to 20.9% (15 mg) for a period of 72 weeks…
Phase III results of Tirzepatide (GLP1 agonist) results in mean weight changes up to 20.9% (15 mg) for a period of 72 weeks #obesity #Tirzepatide https://t.co/uQmQVI6VIS
RT @NatureRevEndo: The original paper -> https://t.co/dJTFgppAUh
The original paper -> https://t.co/dJTFgppAUh
Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/8XqmlWhCPI
Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/O72hunQPYl
RT @medical_xpress: #Diabetes drug helps patients lose never-before-seen amounts of #weight, new study shows @nejm https://t.co/QArdFxQknD…
RT @CristinaDragani: A weekly injection of the antidiabetes drug #tirzepatide, along with a balanced diet and at least 150 minutes of #phys…
【RCT】BMI30以上または27以上で1つ以上の体重関連合併症をもつ非糖尿病の成人へのTirzepatide皮下注は、プラセボ投与と比較して、ベースラインから72週時点での体重減少率および5%以上の体重減少達成割合を増加させた。 #ペ読 https://t.co/X6ey0Hj7mp
#論文紹介 GLP-1作動薬のチルゼパチドの抗肥満効果を調べたNEJM論文 週１回の投与で72週で5mg投与で-15%、10mgで-20%、15mgで-21%（プラセボは-3%）という驚異的な効果があります。かなり期待できそうですね。 https://t.co/xgbhmBpNdJ
RT @BradStanfieldMD: About to do a video on the new weight loss study. I'm beyond excited about the implications this has to turn the tide…
RT @CristinaDragani: A weekly injection of the antidiabetes drug #tirzepatide, along with a balanced diet and at least 150 minutes of #phys…
RT @CristinaDragani: A weekly injection of the antidiabetes drug #tirzepatide, along with a balanced diet and at least 150 minutes of #phys…
A weekly injection of the antidiabetes drug #tirzepatide, along with a balanced diet and at least 150 minutes of #physical activity per week, produced a #weightloss of up to 20% of body weight in #obese adults without #diabetes. https://t.co/1M3b6sDFKZ #healthy #healthylifestyle https://t.co/938TxR1Flc
@DaraKaye @RottenInDenmark This trial was published over the weekend. Side effect breakdown below. Full paper here: https://t.co/xS181MyuaV https://t.co/pSFKUnHzhq
RT @agingdoc1: Tirzepatide Once Weekly for the Treatment of Obesity @NEJM https://t.co/G5adGFppDF
Tirzepatide Once Weekly for the Treatment of Obesity @NEJM https://t.co/G5adGFppDF
RT @BradStanfieldMD: About to do a video on the new weight loss study. I'm beyond excited about the implications this has to turn the tide…
RT @BradStanfieldMD: About to do a video on the new weight loss study. I'm beyond excited about the implications this has to turn the tide…
RT @BradStanfieldMD: About to do a video on the new weight loss study. I'm beyond excited about the implications this has to turn the tide…
RT @BradStanfieldMD: About to do a video on the new weight loss study. I'm beyond excited about the implications this has to turn the tide…
RT @BradStanfieldMD: About to do a video on the new weight loss study. I'm beyond excited about the implications this has to turn the tide…
About to do a video on the new weight loss study. I'm beyond excited about the implications this has to turn the tide on the obesity epidemic. Plus I think this signals the beginning of the end for weight loss and diet gurus (finally!) https://t.co/Yxk8R50RyH
RT @medical_xpress: #Diabetes drug helps patients lose never-before-seen amounts of #weight, new study shows @nejm https://t.co/QArdFxQknD…
RT @medical_xpress: #Diabetes drug helps patients lose never-before-seen amounts of #weight, new study shows @nejm https://t.co/QArdFxQknD…
#Diabetes drug helps patients lose never-before-seen amounts of #weight, new study shows @nejm https://t.co/QArdFxQknD https://t.co/STbbCLKKaU
I have to show my PCP this article. :) https://t.co/q4AcrjUt8X
Tirzepatide Once Weekly for the Treatment of Obesity https://t.co/M96vBRT3w1
TL
G
JD